US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
Shanghai Pharmaceuticals Holdings Company Ltd (PK) (SHPMF) 銘柄情報

Shanghai Pharmaceuticals Holdings Company Ltd (PK) (SHPMF)

1.46

0.00

(0.00%)

終了 6月11日 5:00AM

Shanghai Pharmaceuticals Holdings Company Ltd (PK) (SHPMF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.46

( - )

買値

1.40

売値

1.57

出来高

-

0.00 日の範囲 0.00

1.46 52 週間の範囲 1.53

時価総額

前日終値

1.46

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 9,671,675

発行済株式数

3,708,361,809

配当利回り

0.47 (2.89%)

PER

10.26

1 株当たり利益 (EPS)

1.56

歳入

288.08B

純利益

5.81B

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological d... Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China. 詳細を表示

セクター

Healthcare

業界

Medical Distributors

ウェブサイト

www.sphchina.com

本社

Shanghai, China

設立

1994

Shanghai Pharmaceuticals Holdings Company Ltd (PK) is listed in the Healthcare sector of the その他OTC with ticker SHPMF. The last closing price for Shanghai Pharmaceuticals (PK) was US$1.46. Over the last year, Shanghai Pharmaceuticals (PK) shares have traded in a share price range of US$ 1.46 to US$ 1.53.

Shanghai Pharmaceuticals (PK) currently has 3,708,361,809 shares in issue. The market capitalisation of Shanghai Pharmaceuticals (PK) is US$5.41 billion. Shanghai Pharmaceuticals (PK) has a price to earnings ratio (PE ratio) of 10.26.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	1.46	1.46	1.46	0	0	CS
26	-0.07	-4.57516339869	1.53	1.53	1.46	13	1.46	CS
52	-0.07	-4.57516339869	1.53	1.53	1.46	239	1.52853311	CS
156	-0.5689	-28.0398245355	2.0289	2.0289	0.99163	9425	1.47365509	CS
260	-0.19	-11.5151515152	1.65	2.1	0.99163	7683	1.56773787	CS

SHPMF - Frequently Asked Questions (FAQ)

What is the current Shanghai Pharmaceuticals Holdings Company Ltd (PK) share price?

The current share price of Shanghai Pharmaceuticals Holdings Company Ltd (PK) is US$ 1.46

How many Shanghai Pharmaceuticals Holdings Company Ltd (PK) shares are in issue?

Shanghai Pharmaceuticals Holdings Company Ltd (PK) has 3,708,361,809 shares in issue

What is the market cap of Shanghai Pharmaceuticals Holdings Company Ltd (PK)?

The market capitalisation of Shanghai Pharmaceuticals Holdings Company Ltd (PK) is USD 5.41B

What is the 1 year trading range for Shanghai Pharmaceuticals Holdings Company Ltd (PK) share price?

Shanghai Pharmaceuticals Holdings Company Ltd (PK) has traded in the range of US$ 1.46 to US$ 1.53 during the past year

What is the PE ratio of Shanghai Pharmaceuticals Holdings Company Ltd (PK)?

The price to earnings ratio of Shanghai Pharmaceuticals Holdings Company Ltd (PK) is 10.26

What is the cash to sales ratio of Shanghai Pharmaceuticals Holdings Company Ltd (PK)?

The cash to sales ratio of Shanghai Pharmaceuticals Holdings Company Ltd (PK) is 0.19

What is the registered address of Shanghai Pharmaceuticals Holdings Company Ltd (PK)?

The registered address for Shanghai Pharmaceuticals Holdings Company Ltd (PK) is Shanghai Pharmaceutical Building, Shanghai, 200020

What is the Shanghai Pharmaceuticals Holdings Company Ltd (PK) website address?

The website address for Shanghai Pharmaceuticals Holdings Company Ltd (PK) is www.sphchina.com

Which industry sector does Shanghai Pharmaceuticals Holdings Company Ltd (PK) operate in?

Shanghai Pharmaceuticals Holdings Company Ltd (PK) operates in the Medical Distributors sector

fricassee

fricassee 5分前

More about the iPhone Ultra - Check out the video

https://iphoneislam.com/language/en/2026/04/iphone-ultra-foldable-when-apple-decides-to-break-records-with-a-thickness-of-just-4-5mm/165428

Bobsemptypockets

Bobsemptypockets 5分前

They absolutely will not need billions of dollars. They aren’t in the data center construction business like everyone seems to be confused about. They are in the data center development business and that is identifying, due diligence, entitlement and sell or lease that thing.

rheddle

rheddle 6分前

We all knew EM failed to sell the property in the past after I dug up EM press release and posted the price of the previous one, showing HIRU had negotiated a better deal than the previous people had.

If a deal falls through, it's usually because somebody doesn't bring the money.

VortexDefender302

VortexDefender302 7分前

$RITE SEC 13D Item 5.Interest in Securities of the issuer.(filed on May 10,2026) (A). 6,900,000 representing 100% of the class of shares (B 6,900,000 (C) Acquired the shares in a private transaction through my juristic personas,pursuant to a contract dated 6 May 2026 at a price of $36.23 per sh

mdb1

The US mkts should be down today due to Iran tensions, why is up so much? Huh?

thetinman

thetinman 7分前

PTOP SHAREHOLDERS now know why there's ALWAYS so little information given in these press releases regarding the DETAILS of length of contracts, number of users and projected revenue it's because they're all tied together except 🤣🤣🤣 🔴Hopscotch Air Inc

Wh

thetinman

thetinman 7分前

PTOP SHAREHOLDERS now know why there's ALWAYS so little information given in these press releases regarding the DETAILS of length of contracts, number of users and projected revenue it's because they're all tied together except 🤣🤣🤣 🔴Hopscotch Air Inc

Wh

thetinman

thetinman 8分前

PTOP SHAREHOLDERS now know why there's ALWAYS so little information given in these press releases regarding the DETAILS of length of contracts, number of users and projected revenue it's because they're all tied together except 🤣🤣🤣 🔴Hopscotch Air Inc

Wh

Pisd

...tough crowd these days, hanging in here, gl.. ELVA$...

subslover

subslover 10分前

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidom

Rusty586

Rusty586 10分前

Sad news, had a feeling something was going on as he wasn’t as active on X and had replied to this back in January
https://x.com/georgeasharp/status/2008024762891837846?s=46&t=_SYazYTxU4shaeQR6yxh4w

misterfishman

misterfishman 10分前

I dont encourage others to buy or sell ,i just point out that its an otc subpenny stock no matter how much lipstick you put on it.it is what it is i said this is heading back to trips peeps like me who bought in the trips are selling cause the run is over plain and simple not bashing the stock at al

rack186

rack186 10分前

Iits the one your team pump captain uses.
Secform4.com
Line 1 - Mikah pharmaceutical llc. 267,720 ,000 shares.
The dead end site, you've looked at countless times.
Have a great day !!!

VortexDefender302

VortexDefender302 11分前

$RITE SEC 13D Item 5.Interest in Securities of the issuer.(filed on May 10,2026) (A). 6,900,000 representing 100% of the class of shares (B 6,900,000 (C) Acquired the shares in a private transaction through my juristic personas,pursuant to a contract dated 6 May 2026 at a price of $36.23 per sh

WinstonCup

WinstonCup 11分前

Good excuse L45, but wrong. No shorting here in WDLF land. It's more likely the case that the dumper got rid of their shares before the share price goes to quad zero's. Buyer Beware, do your own dd and you will see what a failure Ken T. and WDLF has been the past 5 years.

US Market News

US Market News 11分前

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid TumorsJune 11, 2026 7:30 AM
Business Wire IM-1617 is a potential first-in-class solid tumor antibody-drug conjuga

US Market News

US Market News 11分前

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia VeraJune 11, 2026 7:30 AM
Business Wire New analyses from the Phase 1 SANRECO study demonstrate potential

eliminate

eliminate 11分前

It sounds like David Rush was involved in this deal too and it needs Kash to locate how many gold bars disappeared under the table on the Titanic too
https://www.nbcnews.com/politics/national-security/cia-officer-arrested-gold-bars-accused-making-top-secret-program-sourc-rcna349032

US Market News

US Market News 11分前

Omdia: Netflix to Reach 400 Million Subscribers by 2031, Maintaining Global Streaming Lead Despite Industry ConsolidationJune 11, 2026 7:32 AM
Business Wire Netflix is forecast to reach nearly 400 million subscribers worldwide by the end of 2031, reinforcing its position as the

CA Market News

CA Market News 12分前

Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of DirectorsJune 11, 2026 7:39 AM
PR Newswire (Canada) class="legendSpanClass"HALIFAX, NS, class="legendSpanClass"June 11, 2026 /CNW/ - Sona Nanotec

nightshade20

nightshade20 12分前

Well here we’re are. Under $.10. I’ll pick it back up at $.04. Hopefully buy then this company will pull some material out of the ground. Doubt it!

arachnodude

arachnodude 12分前

"Vertical control" as the sole-source provider of a proprietary performance material nobody else can make, increases the value of things beyond "just silk." As we've known. The anticipation is getting to everyone! 😬

💥💥💥 BAM !!! 💥💥

Laster

Laster 12分前

I saw the article you were referring to.
I actually have no answer.
Edgemode will need billions of dollars to get this up and running. Where/how do they get the financing?
Will they dilute to a 100 billion shares?

Trooperstocks

Trooperstocks 13分前

$TDTH Update: The launch of TDTH AI Asia & Africa represents more than a geographic expansion—it is the execution of our strategy to build and deploy sovereign-scale digital infrastructure across some of the world’s fastest-growing markets.

Press on TDTH Africa: https://nasdaq.com/pre

Trooperstocks

Trooperstocks 13分前

$TDTH Update: The launch of TDTH AI Asia & Africa represents more than a geographic expansion—it is the execution of our strategy to build and deploy sovereign-scale digital infrastructure across some of the world’s fastest-growing markets.

Press on TDTH Africa: https://nasdaq.com/pre

Shanghai Pharmaceuticals (PK)

Signature Resources

Converge Technology Solu...

iShares MSCI Emerging Ma...

Regular Interest Fixed C...

Parkway Corporate

Direxion Shares ETF Trus...

SITO Mobile (EM)

Mfpr China 23 S

Petroleo Brasileiro ADR

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。